Form 4: OptiNose Director Sandra L. Helton Reports Changes in Beneficial Ownership Following Merger with Paratek Pharmaceuticals

Sandra L. Helton, a director of OptiNose, Inc., reports changes in beneficial ownership of securities following the merger with Paratek Pharmaceuticals, including the conversion of stock options into cash and contingent value rights.

Summary

• On May 21, 2025, OptiNose, Inc. merged with Orca Merger Sub, a subsidiary of Paratek Pharmaceuticals, with OptiNose continuing as the surviving entity.
• As a result of the merger, each outstanding share of OptiNose common stock was converted into the right to receive $9.00 in cash and one contingent value right (CVR).
• The CVR represents the right to receive up to $5.00 in cash upon achievement of specified milestones.
• Outstanding stock options were converted into the right to receive cash equal to the excess of $9.00 over the exercise price, if any.
• Stock options with an exercise price greater than $14.00 were canceled for no consideration.
• Stock options with an exercise price between $9.00 and $14.00 were canceled and converted into the right to receive one CVR, with the amount payable reduced by the difference between the exercise price and $9.00.
• Sandra L. Helton, a director of OptiNose, reported these changes in beneficial ownership.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The merger provides immediate cash but also introduces uncertainty with the CVR. The cancellation of some stock options is a negative for those option holders.

Positives

• Shareholders received $9.00 in cash per share as part of the merger.
• The contingent value right (CVR) provides an opportunity for additional payment of up to $5.00 per share.
• The merger provides liquidity for OptiNose shareholders.

Negatives

• Stock options with exercise prices exceeding $14.00 were cancelled without compensation.
• The value of the CVR is contingent upon the achievement of specific milestones, which may not be met.

Risks

• The contingent value right (CVR) may not result in any payment if the specified milestones are not achieved.
• The success of the merger and the integration of OptiNose into Paratek Pharmaceuticals are subject to various risks.

Future Outlook

The document outlines the terms of the merger agreement and the potential for future payments based on the achievement of milestones outlined in the CVR agreement.

Industry Context

This announcement reflects a trend of consolidation in the pharmaceutical industry, where companies seek to expand their product portfolios and pipelines through mergers and acquisitions.

Comparison to Industry Standards

• Mergers in the pharmaceutical industry often involve a combination of upfront cash payments and contingent value rights (CVRs).
• The structure of this deal, with a cash component and a CVR tied to milestones, is a common approach to bridge valuation gaps and align the interests of both parties.
• Comparable deals include Sanofi's acquisition of Bioverativ, which also included a CVR component.

Stakeholder Impact

• Shareholders receive cash and a potential future payment through the CVR.
• Option holders receive cash or CVRs depending on the exercise price of their options; some options are cancelled.
• Employees may experience changes as a result of the merger and integration with Paratek Pharmaceuticals.

Key Dates

Keywords

merger, OptiNose, Paratek Pharmaceuticals, contingent value right, stock options, beneficial ownership, Form 4